Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Accepts healthy volunteers

Comparison of Raloxifene and Lasofoxifene - A Randomized, Blinded Study of These Drugs and Placebo on Bone Loss

ClinicalTrials.gov ID: NCT00163137

Public ClinicalTrials.gov record NCT00163137. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 12:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Double-Blind Placebo-Controlled Trial Of The Safety, Toleration and Efficacy Of Lasofoxifene 0.25 Mg/D and Raloxifene 60Mg/D For The Prevention Of Bone Loss In Postmenopausal Women

Study identification

NCT ID
NCT00163137
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Ligand Pharmaceuticals
Industry
Enrollment
540 participants

Conditions and interventions

Conditions

Interventions

  • lasofoxifene Drug
  • raloxifene Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
48 Years to 75 Years
Sex
Female
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 30, 2003
Primary completion
Sep 30, 2005
Completion
Sep 30, 2005
Last update posted
Aug 11, 2011

2003 – 2005

United States locations

U.S. sites
72
U.S. states
20
U.S. cities
52
Facility City State ZIP Site status
Pfizer Investigational Site Albany California 94706
Pfizer Investigational Site Berkeley California 94705
Pfizer Investigational Site La Jolla California 92037
Pfizer Investigational Site La Jolla California 92093-0659
Pfizer Investigational Site Oakland California 94609
Pfizer Investigational Site Oakland California 94612
Pfizer Investigational Site Palo Alto California 94304
Pfizer Investigational Site Poway California 92064
Pfizer Investigational Site San Diego California 92103
Pfizer Investigational Site San Diego California 92123
Pfizer Investigational Site San Diego California 92128
Pfizer Investigational Site Newark Delaware 19713-2094
Pfizer Investigational Site Brandon Florida 33511-5964
Pfizer Investigational Site Gainesville Florida 32605
Pfizer Investigational Site Gainesville Florida 32607
Pfizer Investigational Site Key Largo Florida 33037
Pfizer Investigational Site Lake Worth Florida 33461
Pfizer Investigational Site Leesburg Florida 34748
Pfizer Investigational Site Miami Florida 33143
Pfizer Investigational Site Miami Florida 33173
Pfizer Investigational Site Miami Florida 33176
Pfizer Investigational Site Tampa Florida 33607
Pfizer Investigational Site Tampa Florida 33613-3946
Pfizer Investigational Site Tampa Florida 33614-7118
Pfizer Investigational Site West Palm Beach Florida 33407
Pfizer Investigational Site Atlanta Georgia 30308
Pfizer Investigational Site Chicago Illinois 60610
Pfizer Investigational Site Des Moines Iowa 50309
Pfizer Investigational Site Wichita Kansas 67207
Pfizer Investigational Site Portland Maine 04102
Pfizer Investigational Site Bethesda Maryland 20817
Pfizer Investigational Site Gaithersberg Maryland 20886
Pfizer Investigational Site Detroit Michigan 48201
Pfizer Investigational Site Detroit Michigan 48236
Pfizer Investigational Site Southfield Michigan 48034
Pfizer Investigational Site Arden Hills Minnesota 55112
Pfizer Investigational Site Minneapolis Minnesota 55415-1226
Pfizer Investigational Site Albuquerque New Mexico 87102
Pfizer Investigational Site Albuquerque New Mexico 87106
Pfizer Investigational Site Akron Ohio 44312-1647
Pfizer Investigational Site Akron Ohio 44314
Pfizer Investigational Site Cleveland Ohio 44195
Pfizer Investigational Site Portland Oregon 97213
Pfizer Investigational Site Portland Oregon 97220
Pfizer Investigational Site Monessen Pennsylvania 15062
Pfizer Investigational Site Mosessen Pennsylvania 15062
Pfizer Investigational Site Pittsburgh Pennsylvania 15213
Pfizer Investigational Site West Reading Pennsylvania 19611
Pfizer Investigational Site Wyomissing Pennsylvania 19610-2132
Pfizer Investigational Site Wyomissing Pennsylvania 19610
Pfizer Investigational Site Chattanooga Tennessee 37403
Pfizer Investigational Site Chattanooga Tennessee 37412
Pfizer Investigational Site Cordova Tennessee 38018
Pfizer Investigational Site Germantown Tennessee 38138
Pfizer Investigational Site Memphis Tennessee 38119
Pfizer Investigational Site Nashville Tennessee 37203
Pfizer Investigational Site Dallas Texas 75230
Pfizer Investigational Site American Fork Utah 84003
Pfizer Investigational Site Pleasant Grove Utah 84062
Pfizer Investigational Site Provo Utah 84064
Pfizer Investigational Site Salt Lake City Utah 84102
Pfizer Investigational Site West Jordan Utah 84088
Pfizer Investigational Site Chesapeake Virginia 23320
Pfizer Investigational Site Norfolk Virginia 23502
Pfizer Investigational Site Richmond Virginia 23221
Pfizer Investigational Site Richmond Virginia 23225
Pfizer Investigational Site Richmond Virginia 23229
Pfizer Investigational Site Richmond Virginia 23294
Pfizer Investigational Site Richmond Virginia 23454
Pfizer Investigational Site Virginia Beach Virginia 23454
Pfizer Investigational Site Seattle Washington 98104
Pfizer Investigational Site Seattle Washington 98144

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00163137, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 11, 2011 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00163137 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →